Advertisement
Research Article Free access | 10.1172/JCI110638
Find articles by Ghiselli, G. in: JCI | PubMed | Google Scholar
Find articles by Schaefer, E. in: JCI | PubMed | Google Scholar
Find articles by Zech, L. in: JCI | PubMed | Google Scholar
Find articles by Gregg, R. in: JCI | PubMed | Google Scholar
Find articles by Brewer, H. in: JCI | PubMed | Google Scholar
Published August 1, 1982 - More info
Type V hyperlipoproteinemia (HLP) is characterized clinically by hepatosplenomegaly, occasional eruptive xanthomas, and an increased incidence of pancreatitis. These patients have striking hypertriglyceridemia due to increased plasma chylomicron and very low density lipoprotein concentrations in the fasting state, without a deficiency of lipoprotein lipase or its activator protein, apolipoprotein (apo) C-II. ApoE, a protein constituent of triglyceride-rich lipoproteins, has been implicated in the receptor-mediated hepatic uptake of these particles. ApoE has three major alleles: E2, E3, and E4, and the products of these alleles are apoE2, apoE3, and apoE4, respectively. ApoE phenotypes were determined in 30 type V HLP patients as well as in 37 normal volunteers. Among the type V patients, 33.3% were noted to be homozygous, and 40.0% heterozygous for E4 (normal, 2.7 and 21.6%, respectively). These data suggest that apoE4 may play a role in the etiology of the hyperlipidemia in a significant number of type V HLP patients.
Images.
Click on an image below to see the page. View PDF of the complete article